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1. Introduction 
Drug trade names are an important object of study because of the health, legal and 
commercial concerns they represent. For instance, look-alike and sound-alike 
names of drugs contribute to the burden of medication errors, which are a subset of 
adverse events in healthcare. These errors of prescription, dispensing and use 
account for 7000 annual deaths in the US (cf. Kohn et al 2000), and for 25% of 
litigation claims in general medicine practice in the UK (cf. Department of Health 
2000). As might be expected, there is also undocumented and anecdotal evidence. 
The pharmacist co-author of this paper (C.E.) has been witness to two interesting 
scenarios involving two drugs, Virex and Virest. In the first, a client returned to a 
pharmacy to complain that a drug previously sold to him (Virex, for HIV-AIDS) 
was not having the desired effect. Upon closer examination of the original 
prescription, it was discovered that Virest (for herpes), not Virex, is what was 
prescribed and what should have been sold. The second scenario occurs during a 
follow-up visit to a hospital to which C.E. had introduced a drug (Virest) 
manufactured by the company he represents. C.E. was given what was intended as 
cheering news: ‘Virex is now being prescribed.’ Flabbergasted, C.E. protests: ‘No, 
no, my drug is Virest, not Virex.’ Another company and another drug were now 
undeservedly enjoying the fruits of C.E.’s marketing labour (as sales pharmacist). 
 
Invaluable insight into drug trademarks has come notably through initiatives of the 
US Food and Drug Administration (FDA). The rationale for this agency’s keen 
interest can be gleaned from the following admission: ‘FDA has determined that 
many of the medication errors reported to the agency result from medical products 
having proprietary names that look or sound like the names of other medical 
products. Reducing the potential for medication errors due to proprietary name 
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confusion is part of FDA’s ongoing medical product risk management effort’ (cf. 
Department of Health and Human Services 2003). 
 
At a June 2003 public meeting of the FDA to brainstorm on methods for evaluating 
the potential for drug name similarities, there were presentations on: the need to 
carefully think through and plan the phases of a trademark development model 
(Olmstead 2003); the range of factors that make name confusion possible (Lesar 
2003); the need for manufacturers to generate protocol data showing how a 
proposed drug name avoids confusion with an existing name, and supply same to 
the FDA when approval is sought (Hassal 2003); the place of handwriting 
technology in predicting the likelihood of a proposed name being confused with 
another in written prescriptions (Jaszczak 2003); how phonetic and orthographical 
strings (subsequence of characters) can be used to assess the similarity and distance 
of names (Dorr & Kondrak 2003); etc. 
 
In Nigeria, it is rare to find any kind of linguistic research on drug trade names, 
whether conducted from the medical safety standpoint (a perspective that enjoys 
prominence in, say, North American literature), or from the equally important 
ethical-commercial perspective that is particularly dictated by the context of drug 
management in the country. The overall consequence of this dearth is that 
knowledge of issues in drug trade names is arguably rudimentary, to the 
disadvantage of all stakeholders. Drug manufacturers may not be aware of the 
infringement of their rights by competitors through trade name counterfeiting, or 
they may not have a robust framework for thinking through trade naming 
possibilities and for reflecting broadly on the implications of whatever trade names 
are assigned to drugs. Lawyers who have to prosecute trademark cases may not 
have access to useful perspectives for their cases. On their part, regulatory 
authorities may employ rather rudimentary criteria for scrutinizing trade name 
licence applications for drugs to be marketed within national borders. 
 
This article seeks to analyse the semantic motivations underlying drug names 
marketed in Nigeria as well as the morphological processes employed in encoding 
these motivations. In doing this, our objectives are to find out: a) how exhaustively 
available naming resources have been utilized, b) how resourceful manufacturers 
have been in assigning trade names to drugs, c) if and how trade naming 
contributes to unfair trade practices and to the potential for adverse drug events, d) 
the challenges which drug naming practices pose to regulatory authorities and the 
legal framework within which they operate. In order to elaborate on the context 
within which the study derives its significance, we first describe the environment of 
drug administration in Nigeria. 
 
2. The context of drug administration in Nigeria 
There are changes taking place currently in the drug administration environment in 
Nigeria, thanks to the multi-pronged approach of the country’s National Agency for 
Food and Drug Administration and Control (NAFDAC) under the much decorated 
Dora Akunyili. Insight into the state of drug administration in the country’s very 
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recent past can be gleaned through the prism of novel initiatives launched by 
Akunyili’s leadership of NAFDAC. However, to be at a turning point, as drug 
administration in Nigeria currently is, means that there are residues of those 
practices which have been largely tackled by reforms.  
 
Fake and substandard drugs have been a bane of healthcare in Nigeria. A BBC 
Two, July 12, 2005 broadcast (‘bad medicines’) described the quality of drugs sold 
in Nigeria and the international sources of substandard medicines. It also showed 
accounts by patients’ relatives of drug failures (with often irreversible 
consequences) caused by what turned out to be fake and substandard drugs. 
Strikingly, these incidents did not always take place in some corner street patent 
medicine store but also in University Teaching Hospitals.  
 
NAFDAC has, by the admission of all, made tremendous progress on the road to 
ridding Nigeria of fake and substandard drugs. In 1989, for instance, 25% of drugs 
sold in Nigeria were fake and substandard, 25% genuine, and in 50% of cases 
studied the evidence was inconclusive. A 1990 study similarly showed that 54% of 
drugs in ‘every major pharmacy shop were fake, a figure that had risen to about 
80% in the subsequent years.’ (cf. NAFDAC 2005). At the end of 2005, it was 
estimated that over 80% of the drugs marketed in Nigeria were genuine. 
 
Quite a number of factors brought about the situation currently being addressed by 
NAFDAC. For instance, the combination of a tradition of long-distance road travel 
would seem to have spawned a drug hawking industry revolving around intestinal 
motility-inhibiting medicines and closely linked to passenger vehicular movement. 
Initially, diarrheal drugs were the medicines sold, but over time the range 
increased. It was common sight to see – at petrol stations where buses and taxis 
stop over – barely literate vendors, hawking search-light batteries and air-
fresheners alongside antibiotics under all unimaginable weather conditions. Thanks 
to NAFDAC, which has declared this practice illegal and is clamping down on 
perpetrators, the industry is increasingly becoming less visible and may only now 
exist underground. Outright success is probably a tall order because deep-rooted 
practices, bolstered by poverty and low levels of education, make it difficult to 
enforce appropriate measures. Unlike in a pharmacy or a patent medicine store, the 
hawker can sell two of the ten tablets in a sachet if that is what the client can afford.  
 
Health in Nigeria is largely financed through out-of-pocket expenses. This factor 
combines with a myriad of other factors such as the following to create other 
challenges for drug administration: widespread poverty, poor patient–physician 
ratios, questionable educational levels of persons manning drug outlets, a tradition 
of purchase and sale (without prescription) of what are prescription-only-medicines 
(POMs), and so on. Every so often at patent medicine stores and pharmacies, 
clients are seen coming in and complaining of a long list of problems, then offering 
the local currency equivalent of less than a cent, and asking for whatever drug 
description(s) and quantity thereof can address the catalogue of problems. At once 
the vendor, who may be barely literate, is pressured into the role of physician-
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economist, clearly oblivious of the distinction between POMs and over the counter 
(OTC) medicines. Here again, NAFDAC is having drug vendors comply with the 
international practice of selling only on prescription medicines that are so 
classified. Drug vendors are increasingly wary of selling POMs without 
prescription as the client could very well be an undercover NAFDAC agent or a 
security operative. Again, success here is likely to be a tall order because of system 
linkages. If the physician–population ratio is poor or if access to a physician is 
difficult for financial, geographical and other reasons, operators of pharmacies will 
continue to have a steady flow of clients that require POMs but without the 
prescriptions. Since pharmacies are essentially business outfits, business sense is 
likely to prevail. 
 
It is indeed this warped business sense that often exploits the low educational levels 
of the clientele and/or the absence of prescriptions to create a common but 
unfortunate scenario in pharmacies and other drug sales outlets in Nigeria. A 
request by a client for drug XA, which turns out to be unavailable in the given 
pharmacy, is hardly answered in the negative. In the better of two scenarios, the 
vendor says XB is available, implicating to the client that XA and XB are identical. 
In a worse case, XB is simply passed off as XA, with no apparent concerns about 
bioavailability. In the course of writing this article, one of us (BA) went to a 
pharmacy with a request for Ceporex (a Cephalexin-based antibiotic syrup from 
GlaxoWellcome). With no explanation whatsoever, the dispensing pharmacist 
packages Spirodex, a competing product. BA rejects it. An apology is only 
(sarcastically) offered after BA affirms that a client has the right to the brand of 
choice for what might be considered psychological reasons, assuming there are no 
pharmokinetics to worry about.  
 
In sum, the context in which this study is set is one in which drug counterfeiting is 
or has been a problem. It is an environment in which drugs are requested, not on 
the basis of (authorized) prescription, but on the recommendation of a neighbour 
who, for all we know, is barely literate in English and may have mixed up the 
pronunciation of the drug’s English-sounding name. The context is also one in 
which drugs are sold by all manner of persons with questionable credentials and 
with scant regard for prescription; even where there is a prescription, the dictates of 
the bottom-line are such that the client’s right of choice is disregarded. In these 
circumstances, it becomes clear that drug trade naming practices can be a veritable 
source of concern from the health, commercial and similar standpoints. 
 
3. Theoretical framework 
A discussion such as this on the name by which something is called is necessarily 
framed by an outline of concept characteristics and by the word-formation 
processes that give expression to the decisions taken at the concept characteristics 
level.  
 
It is often the case that the name of an object will be motivated by some 
characteristic of that object, in other words, attributes. We interpret Dahlberg’s 
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(1995) account of concept characteristics in terms of a cline, from a high level of 
abstraction or generalization to a low or zero level. See Figure 1 below. 
 
1. Essential characteristics 
1a Essence-constituting characteristics 
1b Essence-consecutive characteristics 
   2. Accidental characteristics 
        2a general accidental characteristics  
     2b specially individualizing characteristics 
 
Figure 1: Typology of concept characteristics 
 
Following Dahlberg, if we take a human being as referent, an example of… 
 
• 1a would be: to have a living body, to have a soul, to have a divine spirit – 
these being according to her the necessary and sufficient conditions. (For a 
drug, this would be a brand attribute like chemical composition or the 
generic on which it is based); 
• 1b would be: (from having a living body) metabolism & reproduction; (from 
having a soul) feeling; (from having a divine spirit) creativity, free-will 
power, etc. (For a drug, this would be a brand attribute like, say, therapeutic 
effect); 
• 2a would be: sex (male, female), height (tall, average, short), etc. (For a 
drug, this would be a brand attribute like the presentation form: tablet, 
caplet, etc.); 
• 2b would be: date of birth, domicile, name of parents, etc. (For a drug, this 
would be a brand attribute like the name of the manufacturer). 
 
When a decision is taken on what characteristics, brand attributes or motifs to 
implement in a name, the next issue is that of the word-forming method that will 
give expression to that decision. Name formation is a peculiar activity in that it 
does not appear subject to all of the same kinds of constraints or rules for forming 
general language words. It is intuitively assumed that, with perhaps the exception 
of compounding, relevant word formation processes would fall into the category of 
what is severally referred to as oddities, unpredictable formations, and so on. Since 
in its treatment of these processes the relevant literature (e.g. Francis 1981, Bauer 
1983, Mathews 1991) sometimes differs in terminology, classification, level of 
generalization, perspective, we outline below our operational acceptation for a 
number of processes relevant to the current context. 
 
1. When two or more words (including names and coinages) combine, or when 
a word combines with a word-part whose underlying base is despite the 
shortening still transparent, and the resulting combination is a hyponym of 
the grammatical head, then we will speak of an endocentric compound. 
Examples: Robert Paracetamol, Moko Chloroquine, Alagbin Plus, Voltaren 
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SR (the latter two being of course left-headed, whereas the former two are 
like all typical English language compounds right-headed). 
 
2. When two or more words or transparent word-parts combine, and there is no 
apparent head within the construction because the real head is actually 
external and is only metaphorically referred to, we will speak of an 
exocentric compound. Examples: Painax (<pain + axe), Pengo (<pain + go) 
– in which the words occupying the traditional position of head refer 
metaphorically to the named medicines. 
 
3. When two or more words (typically proper nouns) combine and no 
meaningful analysis into modifier and head can be made literally or 
metaphorically, then we have a copulative compound. Example: Alka-
Seltzer. (Company mergers often are a source of copulative compounds).  
 
4. When a word is made up of initials and other place holders like numbers, the 
result is abbreviation. Examples: M & B 5, CQP 500. 
 
5. When a word is shortened but its base remains recognizable in the reduction, 
or when two or more shortened words are combined to form a new one that 
is semantically recoverable, then we have clipping. Examples: Clofenac (< 
diclofenac), Emzoquine (< clipped forms of Emzor – name of manufacturer 
– + Chloroquine), Lariam (< malaria). 
 
6. When a word or proper noun combines with an unrecognizable word-part 
(including initialism), or when two word-parts are combined such that one 
or both of the parts is not recognizable, or is only recognized after being 
explained, the process is described as blending. Examples: Emprin 
(<clipped forms of Emzor and Aspirin), Imoceta (<unknown + clipped form 
of paracetamol).  
 
7. When a previously non-existing word is formed with no motivation of any 
kind, the result is word manufacture. Examples: Propon, Daga, Afrim. 
 
To allow them remain basic or no more complicated than they already are, these 
operational definitions have not been encumbered with such otherwise necessary 
specifications as: the nature of the word (orthographic vs. phonetic: recall examples 
painax and pengo); whether letters of a word are written in their correct sequence 
or in some inverse or other order (recall example: Lariam < malaria); and so on. 
The criterion of transparency/recognition which serves to distinguish blending and 
(a compound form of) clipping is a rather subjective one, depending as it is on the 
observer. The perspective that will be adopted here is that of the health professional 
or other persons who, through interest, have gained some familiarity with the drug 
industry in Nigeria (generics of trade names marketed, notable manufacturers, etc.).  
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It is within this framework, then, that we will be analysing (in the manner outlined 
in the next section) the data for this study.  
 
3. Materials & Methods 
Data required for the study is made up of trade names of drugs, and these names are 
sourced from the Emdex Complete Drug Formulary for Nigeria (2005), a published 
reference resource based on the World Health Organization (WHO) model 
formulary. It contains, among others, generic names of drugs, trade names of drugs 
that are registered in Nigeria, features of these drugs (composition, strength, 
presentation form, base, etc), the conditions they treat as well as the names of their 
manufacturers or importers into Nigeria1.  
 
A total of 209 trade names constitute the corpus for this study. These names are 
taken from three drug categories: non-opioid analgesics and antipyretics (66 
proprietary drugs distributed over 6 generics), nonsteroidal anti-inflammatory drugs 
(72 proprietary drugs distributed over 11 generics) and antimalarial drugs (71 
proprietary drugs distributed over 15 generics). Pain/fever and inflammation (the 
first two categories) and malaria (third category) are very common conditions for 
which there is a diversity of generic and proprietary drugs. Only trade names for 
proprietary formulations are of interest to this study.  
 
In addressing the first objective on how exhaustively available naming resources 
have been utilized, the motifs or concept characteristics encoded as names in our 
corpus will be identified as well as the patterns of combination and morphological 
processes. The identification of motifs may be subjective, but it will be seen to be 
intersubjectively verifiable. On the basis of the list of motifs, the number of naming 
options will be determined through a permutation analysis using the following 
formula: 
 
)!(
!
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n
−=  
 
where  
P = Permutation symbol 
n = No. of available motifs (in this case n =13) 
n! = Factorial n = n(n-1)(n-2)...1 
r = No. of motifs in a drug name (in this case r =1, 2 or 3) 
 
The number of possibilities (permutations) will show not just how exhaustively 
naming possibilities have been actually used, but also a sense of the distribution of 
the actual naming patterns over possibilities. What motivation patterns are over- or 
underused? The question will also be asked in respect of morphological processes. 
 
In addressing the second objective on the resourcefulness of manufacturers, we 
draw on the results of a general analysis of the motivations of all trade names and 
the morphological processes that encode these motivations into names. The specific 
Article by Antia, Emoabino & Egbejimba 
 59
data of interest here are those situations where there are several manufacturers 
producing proprietary versions of the same generic and having trade names reflect 
this generic without apparently infringing on one another’s names.  
 
To address the third and fourth objectives on the relationship between, on the one 
hand, trade naming and, on the other, adverse drug events (associated with 
prescribing, dispensing and using), fairness and regulation, several kinds of data 
will be presented, notably data showing a perfidious genericization of trade name 
parts.  
 
3. Results 
3.1. Distribution of trade names over naming possibilities 
Appendices 1 – 8 present data on motivation patterns as well as on the 
morphological processes encoding instances of these motifs into trade names. With 
respect to motifs, the appendices show that forty-four possibilities are used. 
Leaving out instances of the motif referred to as ‘stolen’ in serial numbers 6, 28, 
35, 38, 39, 40, 41 (to which we shall return subsequently), we have thirty-seven 
motivation patterns.  
 
From the standpoint of the typology of characteristics, the corpus exemplifies the 
whole range: motif combinations that highlight essence-constituting characteristics 
like serial no. 18 (generic + base + strength = CQP-500, where CQP=Chloroquine 
Phosphate), no. 25 (condition + generic = malaquine), no. 42 (effect + condition = 
antimal); and motif combinations that slight essential characteristics like no. 2 
(unknown + fortification = Alagbin Plus),  no. 32 (manufacturer + presentation 
form = Emcap), no. 33 (manufacturer + strength = M & B 5), no. 36 (attribute + 
presentation form = toptabs). 
 
Again leaving out the motifs referred to as stolen, we see from appendices 1 – 8 
that, essentially, thirteen motifs are implemented, namely: 1) unknown (often we 
have proper nouns here), 2) generic name, 3) condition (to be treated), 4) 
manufacturer’s name, 5) effect (the therapeutic consequence of drug), 6) attribute 
(expressive, judgmental description of drug), 7) strength (SR: slow release; mg: 
milligram), 8) fortification (e.g. extra, plus, both indicating a combination of 
generics), 9) presentation form (e.g. tablet, capsule, elixir), 10) base (phosphate, 
sodium, etc.), 11) user group (of the drug, e.g. kids), 12) substance (other 
composite besides generic), 13) category (the group to which several generics 
belong, e.g. analgesics, antimalarials). The question now is: just how many naming 
possibilities can these thirteen motifs generate, assuming a maximum of three 
motifs per name?  
 
Using the formula for permutation analysis given earlier, if a drug name were to 
consist of no more than k motifs (where nk ≤≤1 ), the number of possibilities 
(permutations) would be:  
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Therefore, a permutation analysis of the 13 motifs in our corpus, where a drug 
name consists of no more than 3 motifs, gives rise to the following number of 
possibilities: 
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Intuitively, however, certain motif permutations are conceptually or otherwise 
implausible, even though those examples of trade names that implement essence-
irrelevant characteristics tend to suggest that just about any selection is possible. 
We nonetheless assume that some motifs or motif permutations may not (always) 
be possible, and that there would be certain constraints to selections/sequences. For 
instance, the motif ‘fortification’ is not uniformly available because a given drug’s 
composition needs to have been fortified with some other generic for this motif to 
be used. Besides, fortification will necessarily occur in the proximity of ‘generic’. 
The motif ‘effect’ necessarily has to be in the proximity of motif ‘condition’. 
Although it cannot be stated just how many such exceptions there would be2, it 
appears, intuitively at least, that the thirty-seven options actually used in the corpus 
represent a small fraction of the 1885 possibilities. Table 1 below presents a sample 
of patterns (two and three motifs) that have not at all been attested in our corpus. 
 
Generic + user group  Presentation form + generic Generic + base  
Manufacturer + condition + effect  Generic + presentation form Manufacturer + unknown 
User group + effect + condition Fortification + generic Condition + presentation form 
Table 1: Motivation patterns unattested in studied corpus 
 
 
Turning now to morphological processes employed in encoding these motifs, Table 
2 shows the distribution of names according to process. 
 
Occurrences of processes 
Endocentric 
compounds 
Exocentric 
compounds 
Copulative 
compounds
Abbreviation Clipping Blending Word 
manufacture
12 3 1 4 68 95 26 
Table 2: Word formation processes employed in studied corpus 
 
It is obvious from Table 2 that blending and clipping together account for 163 out 
of the 209 trade names. Together the three compound types account for just 16 of 
the total, while word manufacture (or coinage) is used for 26 of the names3. The 
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latter corresponds to single-unit terms with the motivation unknown (cf. appendix 
1). 
 
With respect to our first objective, therefore, it is obvious that many more 
possibilities for trade naming exist than have been actually used in the three drug 
categories under study. Leaving aside for a moment the point about implausible 
selections/sequences, the 37 patterns used out of the 1885 possibilities amounts to 
only 1.9%. We note that some of the most frequent motifs in our trade name corpus 
are: generic (in 134 names), unknown (in 110 names), manufacturer (in 39 names), 
and condition (in 34 names). The least frequent motifs include: user group (in 1 
name) and base (in 1 name). As far as morphological processes are concerned, it is 
obvious for instance that compounds are not nearly as frequently used as clipping 
and blending. 
 
The foregoing will be at the background in the following sections on 
resourcefulness and perfidy. 
 
3.2. Resourcefulness in naming 
Intuitively, there could be a host of parameters for assessing what resourcefulness 
in trade naming is: a) ease of recall; b) ease of pronunciation; c) transparency of the 
drug’s essential characteristics (to health professionals, but also to the clientele); d) 
mirroring of some strategic interest (e.g. corporate identity) or other essence-
consecutive characteristics (presentation form, etc.); e) distinctiveness, that is, 
attaining all or several of the above parameters without demonstrably being liable 
of infringement of other trademarks. Below we shall be concerned with (aspects of) 
parameters c – e. 
 
Paradoxically, motif ‘unknown’ is in absolute terms the second most numerically 
significant motif, after ‘generic’ (cf. appendix 2). From the standpoint of 
transparency of a drug’s characteristics, the 25 instances of single-unit names with 
motif ‘unknown’ are apparently problematic. Informants who are medical students 
or fresh medical graduates claim that recognition of a drug is enhanced when the 
trade name implements motifs that are easily matched with some general 
characteristics, such as chemical grouping (generic), condition treated, effect, etc. 
The learning curve is a lot steeper with trade names that are integrally based on 
proper nouns or motifs that are not generally known. So, within what must be 
considered a tension system of transparency and distinctiveness, the 25 single-unit 
trade names implementing motif ‘unknown’ are very distinctive and are unlikely to 
contribute to name-related medication errors. However, this putative 
resourcefulness loses its value, or translates into a challenge, in settings where, 
because of concern with faking, physicians have to actually know and prescribe 
trade names rather than generics. 
 
By the same token, where there is an attraction to motifs that are transparent, the 
challenge inevitably becomes one of how to maintain some form of distinctiveness. 
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Appendix 2 shows that the motif ‘generic’ is in absolute terms the most frequent, 
with 52 occurrences name-initially and a further 83 occurrences in other positions.  
 
As the data below will show, distinctiveness seems to be achieved through the 
creative use of clipping and through blending of generic name parts with a variety 
of other formants (full, clipped or abbreviated names of manufacturer or of other 
proper names, form of drug, user population, etc.). 
 
Consider Table 3 below which shows that there are three manufacturers with 
naproxen-based products.  
 
Naproxen 
Trade name Manufacturer/importer 
Apo-Naproxen Lahams, Nigerian agent to Apotex 
Pharmaceuticals, Canada 
Hoproxen Hovid (Malaysian). Phamatex is 
Nigerian agent. 
Naxen Swipha (Swiss Pharma, formerly 
Roche) 
Table 3: Attempts at reflecting the generic, Naproxen 
 
Swipha’s ‘Naxen’ is a composite front-back clipping: the generic is clipped in such 
a way that the initial and final syllables of the base remain (‘na + xen’). The middle 
syllable ‘pro’ is thus deleted. Hovid, on its part, uses back clipping (as it deletes the 
initial syllable ‘na’), and the outcome is then blended with the first syllable (‘Ho’) 
of its name. Manufacturer Apotex retains the entire generic name, then blends it 
with a front clipping of its name ‘Apo’.  
 
The deletion of the middle syllable in ‘Naproxen>Naxen’ can also be seen in Table 
4 with the two amodiaquine-based drugs in our corpus.  
 
Amodiaquine 
Trade name Manufacturer/importer 
Amoquin Pharma-Deko 
Camoquin Pfizer 
Table 4: Attempts at reflecting  
the generic Amodiaquine 
 
While manufacturer Pharma-Deko only clips, taking away the third syllable ‘dia’, 
Pfizer blends the outcome of the same process with an initial (unknown, difficult to 
recover) C. Since Camoquine from Pfizer came before Amoquin, manufacturer 
Pharma-Deko would be said to have failed to be sufficiently distinctive if such a 
claim of confusion were ever made. 
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So far, we have seen instances of 2-3 proprietary drug preparations competing for 
use of the generic name. Let us now turn to a situation where 26 trade names are 
able to reflect the generic ‘chloroquine’ and still maintain a measure of 
distinctiveness. Table 5 below presents the relevant data. 
 
 
Chloroquine-based drugs 
Reflecting initial syllable (Chlo) Reflecting initial & final syllables Reflecting final syllable (quine) 
Trade name Manufacturer Trade name Manufacturer Trade name Manufacturer 
Avloclor Reals Kloquin Ranbaxy Assiquine Dizpharm 
Fapchlor Food & Pharma Moko 
chloroquine 
New Healthway Capquine Evans 
Pentaclor Morison   Donaquine Doyin 
Emzoquine Emzor 
Fevaquine David 
Fevokine GSK 
Kidiquine BCN 
L-quine Leady-pharma 
Malaquine Farmex-Meyer 
Mathewquine Daily need 
Maxiquine Vitabiotics 
Miraquine Mirapharm 
Nasmoquin Nasdmu 
Nivaquine May & Baker 
Normaquine Geneith 
Quimal Dana 
Robaquine Swipha 
Samquine Sam 
Silaquine GoldMoore 
Tavquine Justeen 
 
Ultiquine Ulticare-Lyka 
Table 5: Attempts at reflecting generic Chloroquine 
 
 
A new entrant into medical practice in the community where these drugs are 
marketed hardly has a problem associating these trade names with the generic 
chloroquine. Table 5 shows that of the three syllables in the generic name – 
chloroquine – it is the final one that is the most used. ‘Quine’ becomes something 
of a final combining form (Bauer 1983:214) to which a variety of formants 
(manufacturer name, other names, etc.) can be ‘prefixed’. It is interesting that the 
initial orthographic syllable ‘chlo’, in the much fewer instances where it is used in 
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the proprietary versions, does not occur word-initially. Fronting proper names, 
particularly when they reflect the manufacturer, allows for the simultaneous 
attainment of two goals: projecting the manufacturer’s corporate identity and 
reflecting the generic name of the drug. 
 
It is equally instructive to note from Table 5 that even when drug companies 
implement the very same motifs in the names of their drugs, distinctiveness can be 
achieved through sequencing of the motifs. Though in the pair ‘Malaquine’ and 
‘Quimal’ the extent of clipping of the combining motifs is not identical, there is no 
mistaking that both trade names implement the motifs ‘malaria’ and 
‘(chloro)quine’.  Looking at drugs under the different generic name ‘Quinine’, we 
find further confirmation of the resource that sequencing represents: ‘Quinimax’ is 
largely a mirror image of the chloroquine-based ‘Maxiquine’.  
 
While the combining formant ‘quine’ is the hallmark of chloroquine-based 
products, clipped versions of malaria (notably: mal, lari) are more evenly spread 
across all genera of antimalarials. Table 6 shows this. 
 
 
Clippings of malaria as formant 
Mal Generic name Lari Generic name 
Maladrin Chloroquine Lariago Chloroquine 
Malaquine ---- ditto --- Lariam Mefloquine 
Quimal ---- ditto ---- Laridox Sulfadoxine + pyrimethamine 
Malagold Quinine Larimal Amodiaquine + artesunate 
Antimal Sulfadoxine + pyrimethamine 
Malakare ---- ditto --- 
Malcidal ---- ditto --- 
Maldox ---- ditto --- 
Maloxine ---- ditto --- 
Malpan ---- ditto --- 
Malwin ---- ditto --- 
Ridmal ---- ditto --- 
Malafloq Sulfadoxine + pyrimethamine 
+ mefloquine 
 
Table 6: Attempts at reflecting ‘mal’ and ‘lari’ 
 
 
As Table 6 shows, the clipped ‘mal’ is more often used, and more word-initially 
than word-finally.  
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Although we have no explanation why certain drugs are not included in our 
reference resource, the Emdex Formulary, there is a rather interesting pattern that is 
noticeable when some of these non-documented drugs are considered alongside the 
ones in our data. It does seem that even when the motifs in two or more trade 
names are fundamentally the same the specific lexical, orthographical and phonetic 
realisation or name encoding of these motifs may be different. In Table 7 below we 
use the concept of lexical functions to illustrate this. Following Mel’cuk, a lexical 
function is a semantic abstraction, comprising an argument to which is assigned a 
function in order to obtain institutionalized realizations/expressions in language of 
the given function (Antia 2000:137). Supposing a function, Antiver, standing for 
‘not the appropriate or expected form’; in the context of the argument (drug), the 
institutionalized expressions in English would include: fake, substandard, 
adulterated, counterfeit, and so on. 
 
 
Facets Against Cause to end Condition Fortification 
Antimal Ridmal Maladrin 
*Amalar Malcidal Paludrine > 
French: paludisme 
Malarial drugs 
  Paluther 
 
 Painkil  Pentax Plus 
(paracetamol 
500mg + 
caffeine 25mg) 
 Pengo  Zimol Extra 
(paracetamol 
500mg + 
caffeine 30mg) 
 Penstop  
Analgesics 
   
Arthracid Rheumatoid 
arthritis drugs 
 
Romacid 
 
Table 7: Different motif realisations in trade names (*not in Emdex formulary) 
 
 
Notice that the function ‘against’ is realised as ‘anti’ and ‘a’ in malarial drugs; the 
lexical function ‘cause to end’ in analgesics as three verb realisations (kill, go, 
stop); phonological and orthographical clippings of the composites of ‘rheumatoid 
arthritis’ provide two realisations of this condition (arthr and roma) to which ‘cid’, 
a realisation of the lexical function (cause to end) is added. 
 
It is equally interesting to note that some manufacturers have attempted to uniquely 
identify their products by consistently or frequently using the following pattern of 
trade naming: manufacturer’s name (usually front-clipped) blended with some 
other formant (generic name, form of drug, etc.). Table 8 presents the data. 
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Emzor product range Apotex product range Food & Pharma product 
range 
Empirin (~ + aspirin) Apo-Keto SR (~ + Ketoprofen + 
slow release) 
Fapdol (~ + paracetamol) 
Emcap (~ + capsule) Apo-Naproxen (~ + Naproxen) Fapchlor (~ + chloroquine) 
Emzorquine (~ + chloroquine) Apo-Piroxicam (~ + Piroxicam)  
   
Hovid product range Mirapharm product range  
Hostan (~ + unknown) Mira-para (~ + paracetamol)  
Hoproxen (~ + Naproxen) Miraquine (~ + chloroquine)  
Table 8: Corporate identity advertised in trade names 
 
These names have the effect of projecting the corporate identity of the 
manufacturers. A visit to the websites of several of these companies confirms that 
this pattern is one that is quite frequently used. See, for instance, the following 
websites: 
• Emzor Pharmaceuticals: www.emzorpharma.com/html/product_catalog.htm 
• Apotex: www.apotex.ca/Products/EN/Default.asp 
With respect to Apotex, it would appear that all its drugs have the ‘Apo’ prefix. 
 
The question arises as to whether the resourcefulness represented by the use of a 
motif representing corporate identity does not sometimes lead to drug confusion as 
data such as the following might suggest: Barbimol (paracetamol-based) and 
Barbimox (amoxicillin-based). The particular manufacturer, Juhel, wishes to use 
Barbi as its identity marker. 
 
To conclude, what we see in much of the preceding discussion is an almost frenzied 
foraging of generic names and conditions for motifs to be used in trade names. The 
search has seen a most creative use of morphological processes (e.g. clipping and 
blending) and motifs like ‘quine’ and ‘pain’ (some of which are realised 
orthographically, phonetically, or as corruptions of both: kine, pen). When proper 
names (e.g. manufacturers’ names) are thrown into the combination of motifs and 
pharmaceutical lexical functions (each of which can be lexically realised in a 
variety of ways), what we have is a confirmation of the impression that the pool of 
motifs for drug naming is large. It is precisely this potential that invites a rather 
different assessment of the practice of genericizing trade name parts. 
 
3.3. From resourcefulness to perfidy: genericizing of trade name parts 
Besides the naming strategies that are driven by the need to reflect characteristics 
of the drug, there are other strategies that are more concerned with exploiting 
resources of actual trade names. Admittedly, there is no way of knowing whether a 
given mala- or -quine trade name seeks primarily to reflect some characteristic of 
the drug (generic name, the condition it treats, etc.) or is merely a subterfuge for 
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imitating or exploiting an actual trade name. As a result of this dilemma, the 
discussion in this section is limited to the exploitation (by some manufacturers) of 
existing trade names which are not in any way motivated by any attribute of the 
corresponding drugs (generic name, the condition they treat, manufacturer, delivery 
form, etc.). Exploiting such trade names typically has the effect of converting to 
generic what is actually a proper name (or name part), and the practice smacks of 
infringement of trademark.   
 
Let us consider the piroxicam-based drugs in Table 9 below. 
 
Piroxicam-based drugs 
Trade name Manufacturer/importer Trade name Manufacturer/importer
Feldene 
Neimeth (Formerly 
Pfizer Products Plc) Apo-piroxicam Lahams (Apotex) 
Feloxin 
Diamond Remedies 
(Sole agent for 
Tenderwell Ltd, 
England) Artrite Strides Vital 
Felvin 
Greenlife (no foreign 
link) Grevicam Geneith 
Felxicam Hovid Piro  Titan 
Proxisam Sam 
Reumadene LBS 
Ricam GoldMoore 
 Roxiden Fidson 
Table 9: Attempts at genericizing trade name parts (Feldene) 
 
Although not in our corpus and not reflected on Table 9 above, Felwyn and 
Felvacap 20 are two unregistered piroxicam-based drugs that were until recently 
openly marketed in Nigeria. Now, with the exception of Artrite and Reumadene, 
the trade names in the third column of Table 9 can be seen to make use of various 
clipped parts of the generic drug. Apo-piroxicam is a combination of the formant 
‘Apo’ (from the Canadian manufacturer, Apotex) and the generic name.  
 
From the standpoint of genericizing trade name parts, the drug names in the first 
column of the Table are rather interesting. There is no known characteristic of the 
generic, Piroxicam, or of any proprietary preparation that has ‘Fel…’ as name. A 
look at an international resource, the American AHFS Drug Handbook (2003), 
shows that ‘Feldene’ is one of three proprietary versions of Piroxicam on sale in 
US and Canada. This, together with the number of Internet search hits, suggests 
that Feldene is a more established name than Feloxin or Felvin. 
 
Unlike, say, instances of orthographically or phonetically realized ‘consonant + in’ 
(e.g. xin, dene), etc. which have established themselves as common endings for 
drugs (irrespective of drug category), the repeated use of ‘Fel’ must be motivated 
by considerations we shall speculate on in section 3.4. The inference will inevitably 
be drawn against the backdrop of the pool of naming possibilities described earlier. 
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The trade name ‘Panadol’ (generic: Paracetamol; synonym: acetaminophen) is one 
whose final syllable has also been genericized. Consider Table 10 below, which 
lists in the first column some trade names that reflect the generic, and in the third 
column other trade names with questionable motivation. 
 
Select trade names based on paracetamol ( > para-acetyl-amino-phenol) 
Trade name Manufacturer Trade name Manufacturer 
Acamol Dizpharm Panadol GSK (GlaxoSmithKline) 
Barbimol Juhel Chemadol Chemiron 
Fevamol David Fapdol Food & Pharma 
Gatmol Gateway Mathewdol Daily need 
Leadmol Leady-pharma Phardol Pharma-Deko 
Nacemol Nasdmu Remidol Ranbaxy 
Table 10: Attempts at genericizing trade name parts (Panadol) 
 
It is difficult to describe as mere coincidence the replication or genericization of dol 
in the third column of Table 10, or to say that in each case there is a unique 
motivation for this ending. The pioneer preparation is Panadol, which has been 
traded under that name since 1956 (cf. Wikipedia). Again, dol is unlike, say, 
orthographically or phonetically realized forms of ‘consonant + in,’ etc. which are 
common endings for drugs (irrespective of drug category). There is nothing in the 
chemical compound that is dol. Even if the argument were made that ol was 
traceable to the chemical compound, the question would still remain as to why 
other manufacturers felt the need to copy dol from the pioneer preparation. We 
could just as well have had Chemol or Chemanol, Fapol, etc. After all, the popular 
US brand, Tylenol, ends with ol. It should be noted that although there is a generic 
by the name Tramadol (which is also an analgesic), none of the above drugs is 
based on it.  
 
So far we have seen genericization of trade name parts across manufacturers. There 
is an interesting case in our data of in-house replication of part of a trade name. 
Again, the part in question has nothing to do with any of the characteristics of the 
drug. Consider Table 11 below. 
 
Two antimalarials from Swipha 
Trade name Generic name 
Fansidar Sulfadoxine + pyrimethamine 
Fansimef Sulfadoxine + pyrimethamine + mefloquine 
Table 11: In-house genericizing of trade name parts 
 
Assuming, as we are compelled to by the data, that Swipha’s initial trade name, 
Fansidar, represents a blending of Fansi + dar, the question arises as to what the 
motivation for these items is, as they can hardly be related to the generic name, to 
the condition treated, manufacturer, etc. At any rate, by the time manufacturer 
Swipha was ready to launch another antimalarial that combines mefloquine 
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chloride with the compounds of the previously successful Fansidar, it decided to 
front clip Fansidar, blending the result with a front clip of mefloquine. The 
outcome, Fansimef, now makes Fansi look like such popular combining forms as: -
quine, mala, etc. While in the best of possible worlds, this would have come across 
as an excellent strategy for uniquely identifying Swipha’s antimalarial product 
range with the formant Fansi, and protecting this formant from use by competitors 
keen on taking advantage of the market popularity of Fansidar, there is no 
guarantee of this happening in light of the Fel- and -dol cases.  
 
In concluding this section it is obvious that clipping is the major tool for 
genericizing name parts, with blending being the morphology of the finished 
process. 
 
3.4. Trade naming and the challenge of fair trade, safety and regulation 
Our corpus of trade names raises issues related to fair trade practices, efficacy and 
safety of medication, and the regulatory environment within which drug names are 
approved. 
  
A legally registered trade name confers rights and privileges on the name owners, 
and protects them from all such actions that can be construed as undermining the 
privileges appertaining to the exclusive use of the duly registered trade name. As a 
subset of intellectual property, these industrial property rights are obviously 
infringed when it can be demonstrated that, notwithstanding the caveat emptor 
injunction, clients repeatedly and erroneously buy or are made to buy a given 
medicine in the belief that it is the same as the one they wished for.  
 
A quick reaction test (of sameness or difference) administered either aurally or 
visually might see some respondents claiming identity of the following pairs of 
trade names:  
 
Feldene – Felvin 
Fevaquine – Fevokine 
Camoquine – Amoquine  
 
To give an example with the first pair: a potential aural confusion arises from the 
stealing of the initial syllable and the identical placement by both buyer and seller 
of the primary stress on this syllable. If the initial syllable is stressed, then 
confusion is likely to arise. As vowel length (in ene of Feldene and in of Felvin) 
may not be an issue for potential buyers, this would mean that the unstressed 
second syllables share a high front vowel /i/ and an alveolar nasal /n/, and are 
differentiated only by consonants: the alveolar plosive /d/ and the labiodental 
fricative /v/. The foregoing analysis of the degree of phonetic match between the 
two names can be expressed thus: 
 
 
 
F  e  l  d e n e 
 
 
F  e  l  v i n 
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In applying the orthographic measure to any pair, one would be interested in the 
number of steps it takes to convert one name to the other, then dividing the number 
by the length of the longest string (Dorr & Kondrak 2003). Thus, the orthographic 
distance between the Fevaquine – Fevokine pair is 3/9, (0.33), whereas the 
orthographic similarity is 6/9 (0.66). For the pair, Camoquine – Amoquine, the 
distance is 1/9 (0.11), whereas the similarity is 8/9 (0.88). Assuming that in an 
environment with low literacy levels the threshold of orthographic difference in 
two trade names were placed at a minimum of 65%, then these two pairs would fail 
the distinctiveness test. In the light of the numerous naming possibilities described 
earlier, there is hardly any justification (other than perfidious intent) for the 
similarities in names. 
 
It is not only in the mistaken impression of sameness that a manufacturer’s rights 
can be infringed. These rights can be infringed when a drug is named in a way that 
gives the impression that it is from the same stable (manufacturer) as another with 
which the public is already very familiar. How easily the fortunes of the pioneer 
drug, Feldene, can be affected by the other Fel-names can be seen from local 
trading practices in Nigeria. As earlier described, the client’s question ‘do you have 
XB?’ is hardly answered by ‘No.’ The typical vendor’s answer is ‘We have XD’, 
implicating to the client that the available XD is the same as XB. With sound-alike 
name parts, the client who, when confronted with completely different names (XB 
and AG), might have asked a few more questions or insisted on the prescribed XB, 
now lowers his caveat emptor guard and settles for XD. The effect, from a 
commercial standpoint, is that the manufacturers of XB lose out on sales revenue. 
  
In an environment where fake drugs have been of concern, a fake manufacturer 
who chooses to maintain some unique identity even in thievery finds in a 
look/sound-alike name an effective means for passing off the fake drug as being in 
some way related to what the unsuspecting public knows to be the genuine drug. 
Here again, the manufacturer of the genuine drug is losing out on revenue. 
 
It is no doubt to counter occurrences such as these that the local manufacturers of 
Panadol run TV and radio adverts with the message: ‘if it is not Panadol, it is not 
the same thing as Panadol.’ Obviously, a judgement of infringement here would 
have to be contextually circumscribed. Thus, given the time-depth associated with 
the widespread genericization of dol (from Panadol), the use of this formant today 
might elicit less negative assessment compared to that of Fel, which perhaps is also 
more strikingly perfidious because it occurs name-initially. 
 
This aside, the Panadol message is not mere marketing gimmickry. The point is that 
chemical equivalence is not the same as bioavailability. In other words, when drugs 
are compounded on the same generic, formulation variables will markedly affect 
availability. A sodium base for a drug has a relatively faster speed of delivery (i.e. 
absorption) compared to a potassium base for the same drug. Similarly, a patient 
who has been advised to reduce salt-intake would be running a risk with a drug that 
has a sodium delivery base. For instance, in the management of musculo-skeletal 
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pain in a known hypertensive, diclofenac potassium (CataflamR) would naturally be 
preferable to its sodium counterpart (VoltarenR). In effect, an adverse drug event 
can occur when the trade names of two drugs (derived from the same generic) lead 
to the presupposition of identity in pharmokinetic properties. 
 
The situation is of course worse when the name confusion is in respect of drugs that 
treat different conditions. Novadex (in our corpus) is a paracetamol-based 
analgesic, while Nolvadex (not in our chosen corpus, but listed in the same Emdex 
Formulary) is a tamoxifen-based drug for the treatment of breast cancer. The 
orthographic distance between Novaldex and Novadex is 1/8 (0.12), whereas the 
similarity is 7/8 (0.87)! Given what is known of physicians’ handwriting, it is 
attention to accompanying information (such as dosage, strength, sex of patient, 
etc.) that would prevent one drug from being mistaken for the other in a 
handwritten prescription form. 
 
Such confusing pairs can sometimes be the result of a rather lengthy corporate 
identity marker. It was seen earlier that manufacturer Juhel uses Barbi as its 
identity marker. This situation thus leads to a potentially confusing pair like 
Barbimol (a paracetamol-based drug) and Barbimox (an amoxicillin-based drug).  
 
All of the foregoing clearly challenges regulatory authorities and the legal 
environments within which they work. This is as true within a country as it is 
across national borders. It is well within the remit of a national drug administration 
agency to refuse to register a given trade name licence application. Such an agency 
of course can only enforce its powers if (a) it is aware of the perfidious nature of 
the name application, (b) it can find appropriate legal support to back a denial, and 
(c) if it is sufficiently committed to carrying out its mandate. It is one or the other 
factor that explains what must be considered an international industry-wide perfidy. 
To take an example outside of our data, the Indian manufacturer, Rajat, has 
produced a drug for male erectile dysfunction which is being traded under the 
name, Miagra, clearly motivated by Pfizer’s Viagra. In the October 3, 2005 issue of 
the Nigerian daily, Thisday, Pfizer and Nigeria’s drug control agency (NAFDAC) 
alerted the public to the existence on the market of ten brands of what was 
described as ‘Counterfeit Sildenafil Citrate tablets,’ noting that Viagra is the only 
registered brand of this product. Some of the disparaged trade names include: 
Vega, Pangra, Penegra, Pesigra, Ceagra, Jeansiagra, Vinagra. There is absolutely 
nothing in either impotency or Sildenafil Citrate that motivates the replication of 
the tri-, quadri- or quinqui-gram: gra/agra/iagra. 
  
Awareness of the perfidious nature of a name licence application can also be 
hinged on the information management systems and sources available to a drug 
administration agency. Limited access to trade names internationally means a 
narrow base for decision-making as far as trade name licence applications are 
concerned. We notice, for instance, in our data that there is an Aspirin-based drug 
manufactured by a Nigerian company, Emzor Pharmaceuticals, and called Empirin 
(< front clipping of manufacturer name + back clipping of generic). A look at the 
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AHFS Drug Handbook (2003) shows that an Aspirin-based drug exists in the 
American market that goes by the same name, Empirin. A Nigerian patron of 
Emzor visiting the US might consider what he finds there as the American 
packaging of the home product. Of course the reverse situation also holds. The 
need for international cooperation in the processing of trade name applications is 
obvious. 
 
4. Conclusion 
When public health is defined as societal action in guaranteeing collective health, it 
is a statement of what we all from our various disciplinary and other biases and 
standpoints can do to secure our collective health. In previous studies on childhood 
diarrhea (cf. Antia, Omotara, et al 2003), animal care (cf. Antia, Mohammadou, 
Tamdjo 2004), health planning (cf. Antia & Fankep 2004), our point has been to 
show what can be offered by such branches of linguistics as the following: text 
analysis, terminology and sociolinguistics (specifically, multilingualism). In the 
present study, we have shown what morphology, that branch of linguistics that 
deals with the internal structure of words, can offer.  
 
This morpho-semantic study has shown manufacturers targeting a core of motifs or 
brand attributes which are then encoded (often via blending and clipping) into trade 
names. It is a reflection of the resourcefulness of some manufacturers that they are 
able to propose different realisations of this core motif set, and thereby maintain 
some form of distinctiveness. It has also emerged that some manufacturers have 
actually given thought to, and implemented, a systematic and consistent pattern of 
naming their medicines. On the other hand, we have seen trade names that smack 
of perfidy. Remarkable in this respect is the conversion to generic of what is 
otherwise a unique name-part. This and some of the otherwise resourceful naming 
practices have been shown, through a combination of orthographic and phonetic 
measures, to have the potential for causing confusion. The health, commercial and 
regulatory challenges such confusion raises are discussed. 
  
It is no doubt a statement of the significance of the linguistic discipline of 
morphology that its application to the study of drug trade names can provide the 
basis for the following recommendations: 
 
a) National drug administration agencies, such as Nigeria’s NAFDAC, need 
to review trade names already approved by them in order to: identify and 
commend best practices; identify possible safety and industrial rights 
concerns; revoke those trade name licences considered problematic. 
Nigeria’s NAFDAC can reverse itself and revoke names, pursuant to the 
agency’s registration guidelines 2004, which state at section D4 that: ‘Any 
drug whose name, package or label bears close resemblance to an already 
registered product or is likely to be mistaken for such registered product, 
shall not be considered for registration.’ 
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b) These agencies need to periodically review and revamp their trade name 
licensing procedures to make them keep pace with industry-wide issues and 
challenges, including perfidy. There is probably a need to define the 
threshold of non-acceptable resemblance. Indeed, it could be the absence of 
a linguistically defined threshold of (non)acceptable resemblance that has 
seen trademarks make it through the scrutiny net of NAFDAC’s provisions 
in (a) above. 
 
c) Drug manufacturers need to have a rethink on their trade naming 
practices, in light of the possible safety and legal implications of these 
practices. As in some other environments, they should bear the burden of 
proving distinctiveness of a proposed trade name in line with the regulatory 
agency’s standards. There are, in Nigeria, some trade names that derive from 
local languages (e.g. Alagbin Plus, Alabukun powder). There could be some 
sense to exploiting this resource, given that national proficiency in English is 
regularly estimated to be about 30% of the population.  
 
d) There needs to be greater information sharing among national drug 
control agencies. For instance, national databases of approved drug names 
could be linked as a safety valve for look-alike or sound-alike names across 
national boundaries. The importance of such collaboration is better 
appreciated in an age where travel has become very easy. 
 
e) National legislations need to be strengthened in such a way as to make the 
use of confusingly similar trade names actionable under infringement laws, 
and such other provisions as passing off, misrepresentation or other laws 
regulating unfair business practices. 
 
5. Notes  
1 The foregoing may give the erroneous impression that the discussion is primarily 
of Nigerian interest. On the contrary, several of the manufacturers are non-
Nigerian. Whether or not they maintain some local presence (regional or scientific 
office, import agency) under their traditional names, several companies like Pfizer, 
Roche and Bayer have incorporated in Nigeria under different names (Neimeth, 
Swiss Pharma, and Gemini, respectively). Others like Hovid (Malaysian) and Rajat 
(Indian) operate in Nigeria under the names by which they are known in their 
mother countries. 
 
2 It is outside of our current scope to define permissible motif permutations. See 
Nkwenti-Azeh (1994) for a relevant analysis of positional and combinational 
constraints in compound terms from the field of telecommunications. 
 
3 The foregoing is actually a slight simplification of the word forming processes. At 
times, the processes are actually complex, and involve some recursiveness. The 
trade name, Strimol Extra, is first formed from a clipping of the manufacturer’s 
name (Strides Vital) and a clipping of the generic (mol > paracetamol). The 
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outcome, Strimol, is blending. The addition of Extra converts Strimol into a 
grammatical head, and the entire trade name becomes an endocentric compound 
(interpretation: ‘Strimol Extra is a type of the head, i.e. Strimol’). While this 
construction should ideally be reported as blending + endocentric compound (as in 
appendix 4), in Table 2 above it is reported simply under blending. 
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Appendix 1: Motivation unknown (including proper noun) alone or as modifier 
(i.e. in initial position) = 83; total occurrence of unknown in all positions = 109 
 
 Motivation 
pattern 
Examples Generic 
{Category} 
Morphological 
process 
Remarks 
Tabalon Ibuprofen {Anti-
inflammatory} 
1 Unknown    
(no = 25) 
Feldene Piroxicam {Anti-
inflammatory} 
Word 
manufacture 
 
 Unknown       
+ unknown 
(no = 1) 
Alka-
Seltzer 
Aspirin. Synonym: 
acetylsalicylic 
acid; ASA 
{Analgesic} 
Copulative 
compound 
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Alagbin 
Plus 
 
Aspirin. 
{Analgesic} 
 2. Unknown  
+ fortification 
(no = 5) 
Pastin 
Extra 
Paracetamol. 
Synonym: 
acetaminophen 
{Analgesic} 
Endocentric 
compound 
 
3. Unknown  
+ generic  
(no = 44) 
Lapdap Chlorproguanil  
+ dapsone 
{Antimalarial} 
Blending  
Lam 200 Ibuprofen {Anti-
inflammatory} 
 4. Unknown  
+ strength  
(no = 3) Voltaren 
SR 
Diclofenac {Anti-
inflammatory} 
Endocentric 
compound 
 
 
 
SR = slow release
5.  Unknown  
+ generic  
+ fortification 
(no = 1) 
Zimol 
Extra 
Paracetamol. 
{Analgesic} 
Blending  
(+ endocentric 
compound) 
 
6. Unknown  
+ stolen  
(no = 2) 
Mathewdol Paracetamol 
{Analgesic} 
Blending  
7. Unknown  
+ substance  
(no = 1) 
Meracaf Paracetamol 
{Analgesic} 
Blending  
8. Unknown  
+ presentation 
form (no = 1) 
Oruject Ketoprofen {Anti-
inflammatory} 
Blending ject < injection 
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Appendix 2: Generic alone or as modifier (i.e. in initial position) = 52; total 
occurrence of generic in all positions = 134 
 
 Motivation pattern Examples Base {Category} Morphological 
process 
Remarks 
Roxiden Piroxicam  
{Anti-inflammatory} 
Blending 9. Generic + unknown 
(no = 16) 
Ibunex Ibuprofen  
{Anti-inflammatory} 
Blending 
 
10. Generic + unknown 
+ strength (no = 1) 
Arthlon-50 Artesunate 
{Antimalarial} 
Blending  
(+ abbreviation) 
 
Paradana Paracetamol 
{Analgesics} 
Manufacturer name 
is Dana 
11. Generic  
+ manufacturer 
(no= 4) Proxisam Proxicam  
{Anti-inflammatory} 
Blending 
Manufacturer name 
is Sam 
12. Generic  
+ manufacturer  
 
+ strength (no = 1) 
Indobeta-25 Indometacin  
{Anti-inflammatory} 
Blending  
(+ abbreviation) 
Manufacturer name 
is Beta Drugs 
Clofenac Diclofenac  
{Anti-inflammatory} 
Clipping 13. Generic (no = 14) 
Cicam Piroxicam  
{Anti-inflammatory} 
Clipping 
 
Artequin-
600 
Artesunate  
+ mefloquine 
{Antimalarial} 
Blending  
(+ abbreviation) 
14. Generic + strength  
(no = 4) 
Q-300 Quinine Abbreviation 
 
Diclogesic Diclofenac  
{Anti-inflammatory} 
15. Generic + category 
 (analgesic) (no = 4) 
Indogesic Indometacin  
{Anti-inflammatory} 
Clipping  
Quimal Chloroquine 
{Antimalarial} 
16. Generic + condition 
 (no = 2) 
Primalar Sulfadoxine  
+ pyrimethamine 
 {Antimalarial} 
Blending  
17. Generic + condition 
+ fortification  
(no = 1) 
Ibupain 
forte 
Ibuprofen {Anti-
inflammatory} 
Blending  
(+ endocentric 
 compound) 
 
18. Generic + base  
+ strength (no = 1) 
CQP-500 Chloroquine 
{Antimalarial} 
Abbreviation CQ= Chloroquine  
P= Phosphate 
Arsumax Artesunate 
{Antimalarial} 
19. Generic + attribute 
 (no = 2) 
Quinimax Quinine 
{Antimalarial} 
Clipping max < maximum (if 
there were evidence 
of less stronger 
versions, max would 
have been assigned 
under category 
‘fortification’ 
20. Generic + generic 
(no = 1) 
Parafen Paracetamol. 
Synonym: 
Acetaminophen 
{Analgesic} 
Clipping  
21. Generic + substance 
(no = 1) 
Parakaf Paracetamol 
{Analgesic}. 
Caffeine. 
Clipping  
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Appendix 3: Condition/cause alone or as modifier (i.e. in initial position) = 28; 
total occurrence of condition/cause in all positions = 34 
 
 Motivation 
pattern 
Examples Base {Category} Morphological 
process 
Remarks 
Lariam Mefloquine 
{Antimalarial} 
Clipping Lariam<Malaria 
Changed 
sequence of 
letters 
22. Condition  
(no= 3) 
Artrite Piroxicam  
{Anti-inflammatory} 
Clipping < Arthritis 
Reumadene Piroxicam  
{Anti-inflammatory} 
23. Condition/cause 
+ unknown  
(no = 4) Malagold Quinine 
{Antimalarial} 
Blending Rheumatism 
24. Condition  
+ manufacturer  
(no = 1) 
Malpan Sulfadoxine  
+ pyrimethamine 
{Antimalarial} 
Blending Manufacturer 
name is Panvij 
Biotec 
Malaquine Chloroquine 
{Antimalarial} 
25. Condition  
+ generic  
(no = 9) Malafloq Sulfadoxine  
+ pyrimethamine  
+ mefloquine 
{Antimalarial} 
Clipping  
Painkil Paracetamol 
{Analgesic} 
Exocentric 
compound 
 26. Condition  
+ effect (no= 9) 
Penstop Paracetamol 
{Analgesic} 
Exocentric 
compound 
 
27. Condition  
+ presentation 
 form (no = 1) 
Febrilix Paracetamol 
{Analgesic} 
Blending  
28. Condition  
+ stolen (no = 1) 
Reumadene Piroxicam  
{Anti-inflammatory }
Blending  
 
 
Appendix 4: Manufacturer as modifier (i.e. in initial position) = 33; total 
occurrence of manufacturer in all positions = 39 
 
 Motivation 
pattern 
Examples Base {Category} Morphological 
process 
Remarks 
29. Manufacturer +  
generic (no = 24) 
Hoproxen Naproxen  
{Anti-inflammatory}
Blending Manufacturer 
name is Hovid 
30. Manufacturer +  
generic +  
fortification  
(no = 1) 
Strimol 
Extra 
Paracetamol. 
Synonym: 
acetaminophen 
{Analgesic} 
Blending  
(+ endocentric 
compound) 
Manufacturer 
name is Strides 
Vital 
31.  Manufacturer +  
generic +  
strength (no = 1) 
Apo-Keto 
SR 
Ketoprofen  
{Anti-inflammatory}
Endocentric 
compound (+ 
abbreviation) 
SR = slow release 
32. Manufacturer +  
presentation form 
(no = 1) 
Emcap Paracetamol. 
Synonym: 
acetaminophen 
{Analgesic} 
Blending Manufacturer 
name is Emzor 
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33.  Manufacturer + 
strength  (no = 1) 
M & B 5 Paracetamol. 
Synonym: 
acetaminophen 
{Analgesic} 
Abbreviation Manufacturer 
name is May & 
Baker 
34. Manufacturer + 
unknown (no = 
2) 
Vitadar Sulfadoxine + 
pyrimethamine 
{Antimalarial} 
Blending Strides Vitalis 
Chemadol Manufacturer 
name is Chemiron 
35. Manufacturer + 
stolen letter 
sequence/syllable 
(no = 3) 
Phardol 
Paracetamol 
{Analgesics} 
Blending 
Manufacturer 
name is Pharma-
Deko 
 
 
Appendix 5: Attribute as modifier (i.e. in initial position) = 3; total occurrence of 
attribute in all positions = 5 
 
 Motivation 
pattern 
Examples Base {Category} Morphological 
process 
Remarks 
36. Attribute + 
presentation 
form (no=1) 
Toptabs Aspirin 
{Analgesics} 
Exocentric 
compound 
 
37. Attribute + 
generic (no=2) 
Dependol Paracetamol 
{Analgesics} 
Blending  
 
 
Appendix 6: Stolen alone or as modifier (i.e. in initial position) = 6; total 
occurrence of stolen in all positions = 14 
 
 Motivation 
pattern 
Examples Base {Category} Morphological 
process 
Remarks 
38. Stolen (no = 1) Panda  Paracetamol 
{Analgesics} 
Clipping Cf. Panadol 
39. Stolen + 
presentation 
form (no = 1) 
Voltaren 
emulgel 
(cf. 
Voltaren) 
Diclofenac  
{Anti-inflammatory}
Endocentric 
compound 
 
Feloxin 40. Stolen + 
unknown (no=3) Felvin 
Felxicam 
Piroxicam  
{Anti-inflammatory}
‘Fel’ is probably 
taken from the 
pioneer drug in the 
category, 
‘Feldene’. 
41. Stolen + generic 
(no=1) 
Fansimef Sulfadoxine + 
pyrimethamine + 
mefloquine 
{Antimalarial} 
Blending 
‘Fansi’ is probably 
taken from the 
earlier ‘Fansidar’. 
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Appendix 7: Miscellaneous = 4 
 
 Motivation pattern Examples Base 
{Category} 
Morphological 
process 
Remarks 
42. Effect + condition  
(no = 2) 
Antimal Sulfadoxine + 
pyrimethamine 
{Antimalarial} 
Clipping  
43. Presentation form  
+ generic (no = 1) 
Capquine Chloroquine 
{Antimalarial} 
Clipping  
44. Group + generic (no=1) Kidiquine Chloroquine 
{Antimalarial} 
Clipping Kidi >Kiddies
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ABSTRACT 
 
 
 
Drug Trade Names:A Morpho-Semantic Study 
in Resourcefulness and Perfidy 
 
 
Bassey E. Antia*, Christy G. Emoabino* & Cosmas Egbejimba° 
* Department of Languages & Linguistics, University of Maiduguri, Nigeria 
° Phamatex (Nigeria) Ltd 
 
Linguistic analyses of drug trade names are of interest because they reveal the challenges 
of uniquely identifying proprietary medicines and because responses to these challenges 
can have a range of implications: health (medication errors), commercial (compromised 
sales figures of specific brand names), and legal (protection of industrial property rights). 
Regrettably, and to the disadvantage of many stakeholders, these perspectives have 
scarcely been brought to bear on the trade in medicines in a complex environment such as 
Nigeria, which is a microcosm of environments in the developing world.  
 
Based on a corpus of trade names for three categories of medicines (non-opioid analgesics 
and antipyretics, nonsteroidal anti-inflammatory drugs, and antimalarials), we do a 
morpho-semantic analysis of proprietary drug names marketed in Nigeria. In part, our 
objectives are to determine how resourceful manufacturers have been in assigning trade 
names to drugs; to ascertain whether and how trade naming contributes to unfair trade 
practices and to the potential for adverse drug events; to identify challenges which drug 
naming practices pose to regulatory authorities and the legal framework within which 
these authorities operate. 
 
This morpho-semantic study shows manufacturers targeting a core of motifs or brand 
attributes, which are then encoded (often through blending and clipping) into trade names. 
It is a reflection of the resourcefulness of some manufacturers that they are able to propose 
different realisations of this core motif set, and thereby maintain some form of 
distinctiveness. On the other hand, we also see trade names that smack of perfidy or of an 
intention to cause deception. Remarkable in this respect is the conversion to generic of 
what is otherwise a unique name-part. This and some of the otherwise resourceful naming 
practices are shown, through a combination of orthographic and phonetic measures, to 
have the potential for causing confusion. The health, commercial and regulatory 
challenges such confusion raises are discussed. 
 
The study shows the relevance of linguistic scholarship to public health, thus confirming 
and extending some of our previous work: text analysis and childhood diarrhea (Antia, 
Omotara, et al 2003), terminology and animal care (Antia, Mohammadou, Tamdjo 2004), 
multilingualism and health planning (Antia & Fankep 2004), etc. 
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